Treatment of Hypercholesterolemia in 2015

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Statins are proven to reduce cardiovascular events in high-risk hypercholesterolemia patients.
• Current guidelines support statin use but lack data on routine non-statin combination therapy.
• Recent research explores novel therapies to enhance cardiovascular event reduction.

Purpose of the Study:

• To review the evidence for statin use in cardiovascular disease prevention.
• To evaluate the efficacy of adding non-statin medications to statin therapy.
• To examine the role of novel agents like PCSK9 inhibitors in managing cardiovascular risk.

Main Methods:

• Review of randomized controlled trials and observational studies on statins.
• Analysis of guideline recommendations from the American College of Cardiology/American Heart Association.
• Examination of recent clinical trial data, including simvastatin/ezetimibe combination and PCSK9 inhibitor trials.

Main Results:

• Statins are established for primary and secondary cardiovascular event prevention.
• A trial demonstrated a statistically significant, albeit modest, reduction in cardiovascular events with simvastatin plus ezetimibe versus simvastatin plus placebo.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors show substantial LDL-C lowering and are under investigation for cardiovascular outcomes.

Conclusions:

• Statins remain a cornerstone therapy for high-risk patients.
• Combination therapy with ezetimibe may offer additional benefits in specific patient populations.
• PCSK9 inhibitors represent a promising new class of drugs for further reducing cardiovascular risk.